EGFR Exon 20 | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Conferences Trial results

18 October 2023

ESMO 2023 – butterflies for J&J

Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.

Regulatory Trial results

3 October 2023

The end of Exkivity is another win for Rybrevant

Subscribe to EGFR Exon 20